For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials

In a world first, a medicine developed by artificial intelligence may be used to treat patients with obsessive-compulsive disorder. The news is remarkable and hints that in the future, AI may help drug development become faster and more efficiently than ever before. 

The first non-man made drug molecule, DSP-1181, has now entered Phase 1 clinical trials, European Pharmaceutical Review reported. The molecule is a long-acting potent serotonin 5-HT1A receptor agonist and was developed using AI that was the product of a partnership between Japan’s Sumitomo Dainippon Pharma and Exscientia in the UK. The compound was developed in a remarkable time, with AI able to complete in 12 months what typically takes five years. 

The full Forbes article can be viewed at this link.